Previous 10 | Next 10 |
Eiger BioPharmaceuticals Receives Rare Impact Award for Innovation from the National Organization of Rare Disorders (NORD) for the Development and FDA Approval of Zokinvy® (lonafarnib) PR Newswire PALO ALTO, Calif. , June 29, 2021 /PRNewswire/ -- Eig...
Eiger BioPharmaceuticals (EIGR) shares rise nearly 4% premarket after posting positive results from the company's mid-stage trial of avexitide in congenital hyperinsulinism.The treatment "significantly reduced" glucose infusion rate ((GIR)) when evaluated across dose levels (p=...
Eiger BioPharmaceuticals Announces Presentation of Positive Phase 2 Results of Avexitide in Congenital Hyperinsulinism at the American Diabetes Association Virtual 81st Scientific Session - Primary Endpoint of Glucose Infusion Rate Achieved with Significance PR Newswire ...
Eiger BioPharmaceuticals to Present at Jefferies Virtual Healthcare Conference 2021 PR Newswire PALO ALTO, Calif. , May 26, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the develo...
The following slide deck was published by Eiger BioPharmaceuticals, Inc. in conjunction with this event. For further details see: Eiger BioPharmaceuticals Investor Presentation - Slideshow
Eiger BioPharmaceuticals (EIGR): Q1 GAAP EPS of $0.85 beats by $1.09.First quarter 2021 net income was driven by a one-time gain from the sale of the Zokinvy Priority Review Voucher. The company reported $45.9 million as Other Income, Net, which primarily reflects net PRV sale proceeds....
Eiger BioPharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update - Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Phase 3 COVID-19 TOGETHER Platform Study...
Eiger BioPharmaceuticals Announces Peginterferon Lambda to be Added to Multi-Center Phase 3 TOGETHER COVID-19 Study in Brazil - Lambda arm to enroll up to 800 high-risk, non-hospitalized patients - Primary endpoint is reduction of emergency room visits and hospitalizations ...
Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2021 Financial Results and Business Update on Thursday, May 6, 2021 - Live Conference Call and Webcast at 4:30 PM ET PR Newswire PALO ALTO, Calif. , April 29, 2021 /PRNewswire/ -- Eiger B...
Eiger BioPharmaceuticals Appoints Commercial Expert and Industry Veteran Kim Sablich to its Board of Directors PR Newswire PALO ALTO, Calif. , April 22, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceuti...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...